drugset / Trial / NCT01102803

D-Cycloserine to Enhance Cognitive Behavioral Therapy (CBT) for Acrophobia

NCT01102803

Phase 3 Completed 40 enrolled Southern Methodist University
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to investigate the utility of post-session administration of D-cycloserine to enhance fear extinction in a sample of people with acrophobia who will be treated with CBT.

Timeline

Start
2010-04
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Cycloserine Small molecule 50 mg

Indications